Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain
Creative Medical Technology Holdings has received FDA clearance to expand its ADAPT trial evaluating CELZ-201 (Olastrocel) for chronic lower back pain with an additional cohort of patients using moderate opioids. The expansion cohort is over 85% enrolled, leveraging AI-driven patient monitoring for enhanced data collection. Positive interim trial d…